Adma Biologics Inc (NASDAQ: ADMA) has a price-to-earnings ratio that is above its average at 58.94x. The stock has a 36-month beta value of 0.60. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ADMA is 225.68M, and at present, short sellers hold a 5.84% of that float. On February 19, 2025, the average trading volume of ADMA was 2.39M shares.
ADMA) stock’s latest price update
Adma Biologics Inc (NASDAQ: ADMA)’s stock price has soared by 0.71 in relation to previous closing price of 16.17. Nevertheless, the company has seen a gain of 2.55% in its stock price over the last five trading days. schaeffersresearch.com reported 2025-02-12 that Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January.
ADMA’s Market Performance
Adma Biologics Inc (ADMA) has seen a 2.55% rise in stock performance for the week, with a 1.65% gain in the past month and a -19.38% plunge in the past quarter. The volatility ratio for the week is 3.55%, and the volatility levels for the past 30 days are at 3.95% for ADMA. The simple moving average for the past 20 days is -0.34% for ADMA’s stock, with a 4.44% simple moving average for the past 200 days.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at -5.98% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.11% of loss for the given period.
Volatility was left at 3.95%, however, over the last 30 days, the volatility rate increased by 3.55%, as shares surge +2.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.04% lower at present.
During the last 5 trading sessions, ADMA rose by +4.22%, which changed the moving average for the period of 200-days by +148.13% in comparison to the 20-day moving average, which settled at $16.35. In addition, Adma Biologics Inc saw -5.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from Tade Brad L., who sale 15,000 shares at the price of $21.15 back on Nov 22 ’24. After this action, Tade Brad L. now owns 199,433 shares of Adma Biologics Inc, valued at $317,250 using the latest closing price.
Grossman Adam S, the President and CEO of Adma Biologics Inc, sale 48,967 shares at $21.10 during a trade that took place back on Nov 22 ’24, which means that Grossman Adam S is holding 1,989,007 shares at $1,033,204 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.3 for the present operating margin
- 0.49 for the gross margin
The net margin for Adma Biologics Inc stands at 0.18. The total capital return value is set at 0.33. Equity return is now at value 35.55, with 18.42 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at 0.77. The debt to equity ratio resting at 0.48. The interest coverage ratio of the stock is 6.65.
Currently, EBITDA for the company is 5.12 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 10.12. The receivables turnover for the company is 7.63for trailing twelve months and the total asset turnover is 0.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.09.
Conclusion
To sum up, Adma Biologics Inc (ADMA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
